Uthever® NMN NOVEL FOOD Update Download Whitepaper

Overview


EFFEPHARM

NMN is a precursor to NAD+. NAD+ is crucial for energy production, DNA repair, and regulating various cellular processes.

Uthever® NMN, the world’s first large-scale, human clinically-proven NMN brand, has completed the EU NOVEL FOOD Public Consultation. Uthever® is pioneering the EU NOVEL FOOD application process as the first NMN brand to enter the risk assessment stage and is now pending approval. Contact us to plan ahead and get your product market-ready.

Download the whitepaper for industry insights, the latest scientific findings on NMN, and comprehensive global regulatory information.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

The Only & 1st NMN Got Novel Food EFSA Positive Safety Opinion

Paid for by Effepharm Ltd

White Paper

On 11th May 2026, EFSA officially published a positive scientific opinion on EffePharm’s β-NMN as a novel food. This is the first-ever EU official safety endorsement for NMN. UTHEVER® is the 1st NMN ingredient brand to receive EFSA’s positive opinion.

Uthever® NMN: Novel Food Approval Nearing Final Stage

Uthever® NMN: Novel Food Approval Nearing Final Stage

Paid for by Effepharm Ltd

White Paper

One Step Away from EU Market Compliance for NMN. The official positive opinion of Novel Food is expected to be published shortly, which means Uthever® NMN will be the first compliant ingredient.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.